First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis

被引：0
|
作者：
Bobo Zheng
Xin Wang
Mingtian Wei
Quan Wang
Jiang Li
Liang Bi
Xiangbing Deng
Ziqiang Wang
机构：
[1] Sichuan University,Department of Gastrointestinal Surgery, West China Hospital
[2] First Affiliated Hospital of Xi’an Jiaotong University,Department of Gastroenterology
[3] The Fourth Military Medical University,Digestive disease hospital, Xijing Hospital
[4] Chinese Academy of Medical Sciences and Peking Union Medical College,National Cancer Center/Cancer Hospital
来源：
BMC Cancer | / 19卷
关键词：
First line; Cetuximab; Bevacizumab; Wild type; Metastatic colorectal cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Cost-Effectiveness Analysis of Panitumumab Compared with Bevacizumab for First-Line Treatment of Patients with Wild-Type RAS Metastatic Colorectal Cancer in Germany
    Frank, M.
    Lange, A.
    Michailov, G.
    Lebioda, A.
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2016, 21 (04): : 203 - 209
  • [42] Comparative efficacy of cetuximab combined with FOLFOX or CAPEOX in first-line treatment of RAS/BRAF wild-type metastatic colorectal cancer: a multicenter case-control study
    Xu, Chang
    Ren, Jing
    Liu, Changqing
    Gai, Yi
    Cheng, Xiangyu
    Wang, Yusheng
    Wang, Guangyu
    ANTI-CANCER DRUGS, 2025, 36 (05) : 383 - 393
  • [43] CANADIAN ECONOMIC ANALYSIS OF BEVACIZUMAB, CETUXIMAB, AND PANITUMUMAB IN THE FIRST LINE TREATMENT OF KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (MCRC)
    Lawrence, D.
    Maschio, M.
    Yunger, S.
    Easaw, J.
    Aucoin, N.
    Weinstein, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 202 - 202
  • [44] COST-MINIMIZATION ANALYSIS OF BEVACIZUMAB VERSUS CETUXIMAB IN FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER IN KRAS WILD-TYPE PATIENTS IN THE SUPPLEMENTARY HEALTH CARE SYSTEM IN BRAZIL
    Tsuchiya, C. T.
    Kim, H. S. J.
    Maximo, M. F. M.
    Ramos, L. A.
    VALUE IN HEALTH, 2014, 17 (07) : A641 - A641
  • [45] Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis
    Hu, W.
    Xu, W. -S.
    Liao, X. -F.
    He, H. -J.
    MINERVA CHIRURGICA, 2015, 70 (06) : 451 - 458
  • [46] Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer
    Iwamoto, Shigeyoshi
    Maeda, Hiromichi
    Hazama, Shoichi
    Oba, Koji
    Okayama, Naoko
    Suehiro, Yutaka
    Yamasaki, Takahiro
    Suzuki, Nobuaki
    Nagano, Hiroaki
    Sakamoto, Junichi
    Mishima, Hideyuki
    Nagata, Naoki
    JOURNAL OF CANCER, 2018, 9 (22): : 4092 - 4098
  • [47] Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan A Phase 2 Single-Arm Clinical Trial
    Cremolini, Chiara
    Rossini, Daniele
    Dell'Aquila, Emanuela
    Lonardi, Sara
    Conca, Elena
    Del Re, Marzia
    Busico, Adele
    Pietrantonio, Filippo
    Danesi, Romano
    Aprile, Giuseppe
    Tamburini, Emiliano
    Barone, Carlo
    Masi, Gianluca
    Pantano, Francesco
    Pucci, Francesca
    Corsi, Domenico C.
    Pella, Nicoletta
    Bergamo, Francesca
    Rofi, Eleonora
    Barbara, Cecilia
    Falcone, Alfredo
    Santini, Daniele
    JAMA ONCOLOGY, 2019, 5 (03) : 343 - 350
  • [48] First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer
    Ohta, Katsuya
    Ikenaga, Masakazu
    Uemura, Mamoru
    Sakata, Kazuya
    Nishimura, Junichi
    Hata, Taishi
    Matsuda, Chu
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Masaki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 216 - 216
  • [49] First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer
    Uemura, Mamoru
    Kim, Ho Min
    Hata, Tsuyoshi
    Sakata, Kazuya
    Okuyama, Masaki
    Takemoto, Hiroyoshi
    Fujii, Hitoshi
    Fukuzaki, Takayuki
    Morita, Tetsushi
    Hata, Taishi
    Takemasa, Ichiro
    Satoh, Taroh
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Maski
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (02) : 375 - 379
  • [50] Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
    Di Nicolantonio, Federica
    Martini, Miriam
    Molinari, Francesca
    Sartore-Bianchi, Andrea
    Arena, Sabrina
    Saletti, Piercarlo
    De Dosso, Sara
    Mazzucchelli, Luca
    Frattini, Milo
    Siena, Salvatore
    Bardelli, Alberto
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) : 5705 - 5712
12345